Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MEA115588 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncontrolled refractory asthma

Next Previous
Trial Profile

MEA115588 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncontrolled refractory asthma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mepolizumab (Primary) ; Mepolizumab (Primary)
  • Indications Asthma; Eosinophilia
  • Focus Registrational; Therapeutic Use
  • Acronyms MENSA
  • Sponsors GlaxoSmithKline; GSK

    • Most Recent Events

    • 24 May 2023 Meta analysis from NCT01000506, NCT01691521, NCT01287039, NCT01285323, NCT01928771, and NCT01914757, presented at the 119th International Conference of the American Thoracic Society.
    • 01 Mar 2021 Results of post hoc meta analysis of data from the Phase III MENSA and MUSCA studies presented at the 2021 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 16 Mar 2020 Results of a post hoc analysis of data from DREAM, MENSA and MUSCA Efficacy of Mepolizumab Stratified by Baseline Blood Eosinophil Count, presented at the 2020 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top